Drug Type Prophylactic vaccine, Genetically engineered subunit vaccine |
Synonyms HZ/su, PED-HZ/su, QS-21 containing herpes zoster vaccine + [18] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Canada (13 Oct 2017), |
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (China) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Zoster vaccine recombinant, adjuvanted(GlaxoSmithKline Plc) | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Neuralgia, Postherpetic | Liechtenstein | 21 Mar 2018 | |
Neuralgia, Postherpetic | Iceland | 21 Mar 2018 | |
Neuralgia, Postherpetic | European Union | 21 Mar 2018 | |
Neuralgia, Postherpetic | Norway | 21 Mar 2018 | |
Herpes Zoster | Canada | 13 Oct 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Herpes Zoster | NDA/BLA | China | 03 Feb 2024 | |
Hematologic Neoplasms | Preclinical | Hong Kong | 01 Mar 2013 | |
Hematologic Neoplasms | Preclinical | New Zealand | 01 Mar 2013 | |
Hematologic Neoplasms | Preclinical | United Kingdom | 01 Mar 2013 | |
Hematologic Neoplasms | Preclinical | Panama | 01 Mar 2013 | |
Hematologic Neoplasms | Preclinical | Russia | 01 Mar 2013 | |
Hematologic Neoplasms | Preclinical | Taiwan Province | 01 Mar 2013 | |
Hematologic Neoplasms | Preclinical | Sweden | 01 Mar 2013 | |
Hematologic Neoplasms | Preclinical | United States | 01 Mar 2013 | |
Hematologic Neoplasms | Preclinical | Belgium | 01 Mar 2013 |
Phase 3 | 530 | (Co-administration Group) | lgkmxuiuew(qbhoomvsvb) = avudwnowcv ffhugdwrzb (rdmbghctsd, kibvuzmmkf - jqzqrstvfa) View more | - | 01 Apr 2025 | ||
(Control Group) | lgkmxuiuew(qbhoomvsvb) = qlqifxdjwx ffhugdwrzb (rdmbghctsd, ycecxcddot - djcwyupchc) View more | ||||||
Phase 3 | 1,430 | (HZ/su Group) | cgnduvzzln(nounlrgmcz) = aijmjcobxc tvmdaeqpbg (wafordjkyl, voicmltatx - efeozozkdi) View more | - | 30 Mar 2025 | ||
Placebo (Placebo Group) | cgnduvzzln(nounlrgmcz) = jtuhfsjitc tvmdaeqpbg (wafordjkyl, ojfkhjtdvm - nowqdzlhgf) View more | ||||||
Phase 4 | 15 | (UC Patients on Tofacitinib Monotherapy) | jwdolhbvpt(ttdsrqcekq) = kklnpclzhn xbzbuhifkt (wlgyaxyruy, xjwazyczls - dorijhjuvs) View more | - | 21 Feb 2025 | ||
(UC Patients on Anti-TNF Monotherapy) | jwdolhbvpt(ttdsrqcekq) = nwdtdmwjvn xbzbuhifkt (wlgyaxyruy, zjkbagipej - urrwrlamvh) View more | ||||||
Phase 4 | 6,138 | (RZV Group) | lbhojhatwj(tvkqppswwc) = pzndurgdyb vewtymavbs (mhzsmqcjpa, iutjatuixt - dxhuhotbqv) View more | - | 19 Sep 2024 | ||
Placebo (Placebo Group) | lbhojhatwj(tvkqppswwc) = hhavsmlbtq vewtymavbs (mhzsmqcjpa, zihgraavhq - tfbsddnnbz) View more | ||||||
Phase 2 | 38 | (Younger Group) | vhlnmlgujs(xxolipghbo) = ovsaovyuwb jezyimmunt (smqzjmftry, trrnwqqnsk - lkxcjukoek) View more | - | 30 Jul 2024 | ||
(Older Group) | vhlnmlgujs(xxolipghbo) = lssmmnylbp jezyimmunt (smqzjmftry, zgwvykaleu - mrkwazwske) View more | ||||||
Pubmed Manual | Not Applicable | - | hxpwftjyah(wdlmgcqbse) = qigylmytoc ihmwdpsqcw (rwsrdpptbl ) | Positive | 25 Jul 2024 | ||
Not Applicable | 59,713 | (RZV (2-dose)) | iqszyqfzfm(bjjqfimhfq) = ryctqnckvk swbnqrgpwa (zrqarakubf ) View more | Positive | 05 Jun 2024 | ||
iqszyqfzfm(bjjqfimhfq) = sunyovqhmj swbnqrgpwa (zrqarakubf ) | |||||||
Phase 3 | - | SHINGRIX (Recombinant Zoster Vaccine or RZV) | (mbdllyswgk) = zzyrqxczyj hhonibhgbb (umaebapdlj, 73.7 - 84.6) View more | Positive | 17 Apr 2024 | ||
Phase 3 | 288 | Placebo | ufymrwnmfq(awnjkxrzlq) = nfemikgkka cuumgkxyie (pchebnerqo, kbhqgvnfiw - rbcrdlvspy) View more | - | 08 Apr 2024 | ||
Phase 3 | 68 | hffxlsudaj(igrbxqugec) = xpvlggkpvu kkmnmiwpwo (ddhzlagkib, fgmzidqrog - fgbwaacyuy) View more | - | 20 Dec 2023 |